Fundz

Lipella Pharmaceuticals

PITTSBURGH, Pennsylvania, United States · Biopharma, Biotechnology, Healthcare

Lipella is a biotechnology company with a focus on supportive care to cancer survivors who acquire hemorrhagic cystitis, also called radiation cystitis, when hemorrhagic cystitis occurs after pelvic radiation, as well as improved surveillance and imaging of patients with a history of transitional cell carcinoma. We are also applying our proprietary drug delivery to the oral mucosa for the treatmen

Key facts

Headquarters
PITTSBURGH, Pennsylvania, United States
Employees
5
Industries
Biopharma, Biotechnology, Healthcare
Status
Public (LIPO)
Website
lipellapharmaceuticals.com
LinkedIn
Company page

Recent activity at Lipella Pharmaceuticals

  • : SEC 8-K (1.03):
  • : SEC 8-K (1.03): On March 30, 2026, Lipella Pharmaceuticals Inc. and certain of its subsidiaries filed voluntary petitions for relief under Chapter 11 in the Bankruptcy Court for the Western District of Pennsylvania. This filing indicates that the company is undergoing a bankruptcy process, which poses substantial risks to its shareholders. As the company is now in Chapter 11, trading in its common stock is considered highly speculative, and there could be a significant disconnect between stock prices and potential recoveries for shareholders in the bankruptcy proceedings.
  • : SEC 8-K (5.02): On February 3, 2026, Lori A. Birder notified Lipella Pharmaceuticals Inc. of her resignation from the Company's Board of Directors, effective immediately. Dr. Birder's resignation was not due to any disagreements with the Company regarding its operations, policies, or practices. This change in the board composition could impact the governance and strategic direction of Lipella Pharmaceuticals in the near term.
  • : SEC 8-K (5.02): On February 3, 2026, Lori A. Birder resigned from her position on the Board of Directors of Lipella Pharmaceuticals Inc., effective immediately. Her resignation was confirmed not to be related to any disagreements concerning the Company's operations, policies, or practices. This change may signal a shift in governance and could have implications for the strategic direction of the company. The timing of her departure immediately before the reporting date highlights the absence of any planned transition or succession announcement.
  • : SEC 8-K (5.02): On October 20, 2025, Naoki Yoshimura informed Lipella Pharmaceuticals Inc. of his decision to retire from the Company’s Board of Directors, effective December 31, 2025. This retirement is not due to any disagreements with the Company's operations or policies. The announcement highlights a planned transition in the Board, which may impact the Company's governance structure going forward. The filing underscores the smooth succession process as Dr. Yoshimura serves until the end of the year.
  • : LIPELLA PHARMACEUTICALS
  • : LIPELLA PHARMACEUTICALS
  • : Lipella Pharmaceuticals Closes $1.28 Million Direct Offering of Common Stock Under Nasdaq Rules (date Fundz recorded it)
  • : LIPELLA PHARMACEUTICALS
  • : LIPELLA PHARMACEUTICALS

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Lipella Pharmaceuticals funding history

DateRoundAmount
Mar 2025Seed$9K
Dec 2024Seed$2.6M
Jul 2024Venture$120K
Oct 2023Seed$3.1M
Nov 2020Seed$405K

Leadership

  • Jonathan Kaufman, Executive Officer, Director
  • Michael Chancellor, Director
  • THOMAS JR., Director
  • DAVID BATTLEMAN, Director

Verified email and direct lines for Lipella Pharmaceuticals’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

Lipella Pharmaceuticals files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Companies similar to Lipella Pharmaceuticals

  • Savara Inc · Biopharma, Biotechnology, Healthcare, Health Care, Medical, Pharmaceutical, Therapeutics
  • Aquestive Therapeutics, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Medical, Pharmaceutical, Therapeutics
  • Os Therapies · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
  • Galmed Pharmaceuticals Ltd · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
  • Abivax · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics

About Lipella Pharmaceuticals: questions and answers

What does Lipella Pharmaceuticals do?

Lipella is a biotechnology company with a focus on supportive care to cancer survivors who acquire hemorrhagic cystitis, also called radiation cystitis, when hemorrhagic cystitis occurs after pelvic radiation, as well as improved surveillance and imaging of patients with a history of transitional cell carcinoma. We are also applying our proprietary drug delivery to the oral mucosa for the treatmen

Where is Lipella Pharmaceuticals headquartered?

Lipella Pharmaceuticals is headquartered in PITTSBURGH, Pennsylvania, United States.

How many employees does Lipella Pharmaceuticals have?

Lipella Pharmaceuticals has about 5 employees.

Has Lipella Pharmaceuticals raised funding?

Yes. Fundz has recorded 5 funding events for Lipella Pharmaceuticals. The most recent, Seed of $9K, was in Mar 2025.

What is the latest news on Lipella Pharmaceuticals?

On Oct 21, 2025, SEC 8-K (1.03):

Is Lipella Pharmaceuticals a public company?

Yes. Lipella Pharmaceuticals is publicly traded under the ticker LIPO.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Lipella Pharmaceuticals across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.